American Marconi Wireless News - Cosmos Health Submits Patent Application for Allergic Inflammation Therapy by Leveraging AI Drug Repurposing; Allergy Treatment Market Valued at $23.5 Billion

The application, filed under Application Number N2039646 in collaboration with Cloudpharm and the National Hellenic Research Foundation, with the support of the pharma patent expert team at NLO, represents a significant step in the Company's efforts to develop cutting-edge therapeutic options for inflammatory conditions.

The patent is supported by predictive insights from Cosmos Health's AI-powered Cloudscreen drug repurposing platform, combined with recent experimental data. These findings highlight the potential of a repurposed marketed drug to modulate key inflammatory pathways through a novel mechanism of action identified by the inventors.

These advancements reaffirm Cosmos Health's commitment to tackling severe allergic conditions and delivering innovative treatments to improve patient care and quality of life.

Allergic Inflammation

Allergic diseases are characterized by an immune system overreaction to typically harmless substances, such as pollen, dust, or certain foods. Over recent decades, the prevalence of allergic conditions has risen significantly, with BMJ Open 2024 reporting that they now affect approximately 10-30% of the global population. These conditions range from mild seasonal allergies to severe reactions that significantly impact quality of life, underscoring the urgent need for effective treatments.

Global Market Overview

According to Imarc Group, the global allergy treatment market has been experiencing substantial growth, driven by the increasing prevalence of allergic conditions and advancements in therapeutic options. In 2024, the market was valued at approximately $23.5 billion and is projected to reach $37.0 billion by 2033, reflecting a compound annual growth rate (CAGR) of 4.92% during the forecast period.

Greg Siokas, CEO of Cosmos Health, stated: "This patent application is a critical addition to our intellectual property portfolio, reinforcing our dedication to addressing the growing challenges of allergic conditions. By leveraging our AI-driven drug repurposing platform, we continue to push the boundaries of innovation to develop impactful solutions that improve patient care worldwide."

About Cosmos Health Inc.

Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, as well as LinkedIn and X.

Forward-Looking Statements

With the exception of the historical information contained in this news release, the matters described herein, may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by, or that otherwise, include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could", are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements, involve unknown risks and uncertainties that may individually or materially impact the matters discussed, herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company's ability to raise sufficient financing to implement its business plan, the impact of the COVID-19 pandemic and the war in Ukraine, on the Company's business, operations and the economy in general, and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward- looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website (www.sec.gov). The Company disclaims any intention or obligation to update, or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact:

BDG Communications
[email protected]
+44 207 0971 653

SOURCE: Cosmos Health Inc.

View the original press release on ACCESS Newswire

P.Martin--AMWN